FDA approves Pfizer’s TUKYSA for front‑line maintenance in HER2‑positive metastatic breast cancer
The U.S. Food and Drug Administration granted approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a maintenance therapy for adults with unresectable locally advanced or metastatic HER2‑positive breast cancer after induction treatment. The decision is based on the HER2CLIMB‑05 Phase 3 trial, which showed a significant reduction in disease progression risk and an extension of median progression‑free survival. Pfizer announced the approval on October 7, 2026.
Why it matters
The approval adds a new front‑line maintenance indication for TUKYSA, expanding its market potential. TECHi notes that the drug contributed roughly 0.9% of Pfizer’s second‑quarter revenue, so the label expansion could increase its sales share, though no incremental earnings forecast was provided.
Key facts
- 1The FDA approved TUKYSA with trastuzumab and pertuzumab for maintenance treatment of HER2‑positive metastatic breast cancer after induction therapy. marketscreener.com
- 2The HER2CLIMB‑05 trial showed a 35.9% reduction in the risk of disease progression or death (hazard ratio 0.64, 95% CI 0.51‑0.80, p<0.0001). marketscreener.com
- 3Median investigator‑assessed progression‑free survival was 24.9 months with TUKYSA versus 16.3 months with placebo, a difference of 8.6 months. marketscreener.com
- 4Serious hepatotoxicity occurred in 3.9% of patients receiving TUKYSA, including one fatal drug‑induced liver injury. marketscreener.com
- 5The trial randomized 326 patients to TUKYSA plus trastuzumab and pertuzumab and 328 patients to placebo plus trastuzumab and pertuzumab. marketscreener.com
- 6TUKYSA accounted for about 0.9% of Pfizer’s Q2 revenue, and U.S. sales of the product declined 11% in that quarter. techi.com
Summary written by AlphAI from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.